U.S. Markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
294.08+6.16 (+2.14%)
At close: 4:00PM EDT

294.01 -0.07 (-0.02%)
After hours: 7:58PM EDT

People also watch
CELGREGNGILDAMGNALXN
Full screen
Previous Close287.92
Open291.16
Bid294.01 x 100
Ask302.00 x 500
Day's Range290.29 - 296.91
52 Week Range244.28 - 329.83
Volume1,684,310
Avg. Volume1,430,753
Market Cap62.18B
Beta0.53
PE Ratio (TTM)18.42
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock
    Fortune8 hours ago

    Goldman Sachs Bet on Biogen’s Potential Landmark Alzheimer’s Drug Props Up Stock

    Goldman analysts think the drug could eventually ring in $12 billion in sales if approved.

  • American City Business Journals10 hours ago

    ​Biogen gains $1B in value after Goldman Sachs touts Alzheimer’s drug

    Biogen Inc. gained more than $1 billion in market value Wednesday morning after Goldman Sachs, one of the world’s largest investment banks, added the drug developer to its closely-watched Equity Conviction List. Goldman Sachs analysts Terence Flynn and Cameron Bradshaw issued a research note this morning announcing that Cambridge-based Biogen (BIIB) was added to the list, which is essentially a strong recommendation to general investors to buy stock in a certain company. In their research note, Flynn and Bradshaw pointed specifically to Biogen’s experimental drug to treat Alzheimer’s disease, called aducanumab, as a prime reason for the company’s inclusion on the list.

  • CNBC12 hours ago

    Goldman has a new favorite biotech because of potential Alzheimer's blockbuster

    Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug.